Navigation Links
Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Date:12/28/2007

iance may receive milestone payments on future sales.

Zensana(TM) (ondansetron HCI) Oral Spray:

In August 2007, Par Pharmaceutical, Inc. acquired the North American commercial rights to Zensana(TM) from Hana Biosciences, Inc. Ondansetron is used to prevent nausea and vomiting after chemotherapy, radiation and surgery. Following successful development and approval, Zensana(TM) could be among the first in its class of 5-HT3 antagonist anti-emetic therapies to be available in an oral spray form.

Under a development agreement with Novadel Pharma, Inc., Par has completed its reformulation of Zensana(TM) and is preparing for the requisite studies to reconfirm the product's pharmacokinetic profile and confirm stability acceptability. These studies are expected to be completed by the end of 2008 with an NDA to be filed shortly thereafter.

In return for the North American commercial rights to Zensana(TM), Par made a $5 million equity investment in Hana. In addition, Hana may receive future milestone payments and royalties on future sales of the product.

John MacPhee, president of Strativa Pharmaceuticals, said, "We are excited about our current pipeline and look forward to bringing these innovative treatment options to patients and their healthcare providers. In addition, we will continue to pursue products that leverage our commercial presence and expertise in supportive care in oncology and AIDS."

About Strativa

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Supported by Par's financial and organizational capabilities including substantial cash resources, Strativa Pharmaceuticals is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the resources to prepare products for introduction and to help ensure their success after
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Introducing Strativa Pharmaceuticals
2. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
3. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: ... to treat life-threatening diseases, today announced that it will ... and webcast on Thursday, August 13, 2015 at 4:30 ... will follow the release of fiscal 2016 first quarter ... available approximately two hours after the call at the ...
(Date:8/3/2015)... August 3, 2015 According to ... 3D Cell Culture: Asia to ... Research, the global 3D cell culture market was valued at US$ ... at a CAGR of 29.1% to account for US$ ... with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell culture ...
(Date:7/31/2015)... VEGAS , July 31, 2015 ... seek resources that help them drive positive health ... a vital source of patient care in their ... annual tradeshow and conference, AmerisourceBergen announced a ... its Pharmacy Services Administration Organization and help independent ...
(Date:7/31/2015)... ... , ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin ... has been accepted by AOAC International as Official First Action method. The AOAC ... by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... by scientists at Emory University will allow researchers ... variations that may have serious consequences for health ... research protocol allows scientists to extract and enrich ... among individuals using DNA resequencing methods. , The ...
... &,Bioressources Inc. (Neptune) (NASDAQ.NEPT - TSX.V.NTB), "Neptune" today,announced its results for the ... - First Quarter ended August 31, 2007:, ... for the first ... - EBITDA increased by 10% to $332,000 compared ...
... ConsumerLab.com Quality Standards, HOFFMAN ESTATES, Ill., Oct. ... consumer products which failed quality testing,ConsumerLab.com anonymously purchased, ... sold by CNCA, a leading national distributor,of premium ... promote general health and wellness., "ConsumerLab.com testing ...
Cached Biology Technology:New method of selecting DNA for resequencing accelerates discovery of subtle DNA variations 2Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update 2Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update 3CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 2CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 3
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... it can damage blood vessels and increase the risk of ... he can thin the human blood by subjecting it to ... physics at Temple University, has pioneered the use of electric ... engines and pipelines. Now, he is using the same magnetic ...
... coastal areas in Africa can rarely utilise their entire fishing ... near the coast. Research carried out by economist Kofi Vondolia ... of fish stocks is significant to fish management. ... allows foreign fishing fleets to utilise the zones further out ...
... the Virginia Institute of Marine Science (VIMS) shows that jellyfish ... altering marine food webs by shunting food energy from fish ... frequency of jellyfish blooms in coastal and estuarine waters around ... impact on marine food webs is likely to increase into ...
Cached Biology News:Using magnets to help prevent heart attacks 2Optimum tax on foreign fishing in Africa protects stocks and domestic fishing 2Jellyfish blooms shunt food energy from fish to bacteria 2Jellyfish blooms shunt food energy from fish to bacteria 3
... N. Fernandez and G. Butcher (1998). • ... of much research in the immunology area. ... of MHC proteins and in their function ... now faced with the prospect of tackling ...
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
... mutS and ES1301 mutS are mismatch repair ... these strains prevents repair of the newly ... mutation efficiencies and making them helpful in ... Sites II Mutagenesis Systems. Both ES1301 and ...
Biology Products: